SQZ Biotechnologies Stock Forecast, Price & News

SQZ Biotechnologies (NYSE:SQZ) Frequently Asked Questions

Is SQZ Biotechnologies a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SQZ Biotechnologies in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SQZ Biotechnologies stock.
View analyst ratings for SQZ Biotechnologies or view top-rated stocks.

What stocks does MarketBeat like better than SQZ Biotechnologies?

Wall Street analysts have given SQZ Biotechnologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SQZ Biotechnologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting SQZ Biotechnologies?

SQZ Biotechnologies saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,230,000 shares, a decline of 20.1% from the August 15th total of 1,540,000 shares. Based on an average daily volume of 174,200 shares, the short-interest ratio is presently 7.1 days. Approximately 6.5% of the shares of the stock are short sold.
View SQZ Biotechnologies' Short Interest.

When is SQZ Biotechnologies' next earnings date?

SQZ Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, December 9th 2021.
View our earnings forecast for SQZ Biotechnologies.

How were SQZ Biotechnologies' earnings last quarter?

SQZ Biotechnologies (NYSE:SQZ) issued its quarterly earnings data on Tuesday, August, 3rd. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.11. The company had revenue of $4.54 million for the quarter, compared to analyst estimates of $6.24 million. SQZ Biotechnologies had a negative trailing twelve-month return on equity of 74.70% and a negative net margin of 346.39%.
View SQZ Biotechnologies' earnings history.

What price target have analysts set for SQZ?

5 equities research analysts have issued 12 month target prices for SQZ Biotechnologies' stock. Their forecasts range from $37.00 to $40.00. On average, they expect SQZ Biotechnologies' share price to reach $38.33 in the next twelve months. This suggests a possible upside of 155.9% from the stock's current price.
View analysts' price targets for SQZ Biotechnologies or view top-rated stocks among Wall Street analysts.

Who are SQZ Biotechnologies' key executives?

SQZ Biotechnologies' management team includes the following people:

• Dr. Armon R. Sharei, Co-Founder, Pres, CEO & Director (Age 34, Pay $692.57k)
• Ms. Teri Loxam, Chief Financial Officer (Age 49, Pay $633.03k)
• Mr. Lawrence J. Knopf, Gen. Counsel & Sec. (Age 59, Pay $474.45k)
• Dr. Oliver Rosen, Chief Medical Officer (Age 57, Pay $557.29k)
• Mr. Micah Zajic, Chief Bus. Officer (Age 40, Pay $288.65k)
• Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 72)
• Dr. Howard Bernstein, Chief Scientific Officer (Age 64)
• Mr. David First, Chief People Officer (Age 57)

Who are some of SQZ Biotechnologies' key competitors?

Some companies that are related to SQZ Biotechnologies include Ocugen (OCGN), Valneva (VALN), Replimune Group (REPL), Immunocore (IMCR), AlloVir (ALVR), Atara Biotherapeutics (ATRA), Inhibrx (INBX), Sangamo Therapeutics (SGMO), Agenus (AGEN), Vaxcyte (PCVX), Coherus BioSciences (CHRS), Krystal Biotech (KRYS), bluebird bio (BLUE), Century Therapeutics (IPSC) and Scholar Rock (SRRK).
View all of SQZ's competitors.

When did SQZ Biotechnologies IPO?

(SQZ) raised $75 million in an initial public offering on Friday, October 30th 2020. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Securities and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

What is SQZ Biotechnologies' stock symbol?

SQZ Biotechnologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "SQZ."

Who are SQZ Biotechnologies' major shareholders?

SQZ Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional investors include 683 Capital Management LLC (4.90%), BlackRock Inc. (4.34%), Maverick Capital Ltd. (3.51%), Vanguard Group Inc. (3.18%), State Street Corp (1.02%) and Geode Capital Management LLC (0.87%).

Which major investors are buying SQZ Biotechnologies stock?

SQZ stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., 683 Capital Management LLC, Vanguard Group Inc., State Street Corp, JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, and Geode Capital Management LLC.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SQZ Biotechnologies' stock price today?

One share of SQZ stock can currently be purchased for approximately $14.98.

How much money does SQZ Biotechnologies make?

SQZ Biotechnologies has a market capitalization of $420.14 million and generates $21 million in revenue each year. The company earns $-50,520,000.00 in net income (profit) each year or ($9.35) on an earnings per share basis.

How many employees does SQZ Biotechnologies have?

SQZ Biotechnologies employs 98 workers across the globe.

What is SQZ Biotechnologies' official website?

The official website for SQZ Biotechnologies is www.sqzbiotech.com.

Where are SQZ Biotechnologies' headquarters?

SQZ Biotechnologies is headquartered at 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472.

How can I contact SQZ Biotechnologies?

SQZ Biotechnologies' mailing address is 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472. The company can be reached via phone at 617-758-8672 or via email at [email protected].